Arctigenin

Drug Profile

Arctigenin

Alternative Names: Arctium lappa extract; ARG; Burdock fruit extract; GBS-01

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator National Cancer Center (Tokyo)
  • Developer Kracie Pharma; National Cancer Center (Tokyo); Toyama Medical and Pharmaceutical University
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 03 Oct 2016 National Cancer Center Hospital East and Kracie Pharma completes a phase II trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in Japan (UMIN000010111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top